Biogened S.A. (WSE:BGD)

Biogened Statistics

Total Valuation

Biogened has a market cap or net worth of PLN 78.11 million. The enterprise value is 98.14 million.

Market Cap	78.11M
Enterprise Value	98.14M

Important Dates

The next estimated earnings date is Monday, May 12, 2025.

Earnings Date	May 12, 2025
Ex-Dividend Date	Sep 12, 2024

Share Statistics

Biogened has 2.46 million shares outstanding.

Current Share Class	n/a
Shares Outstanding	2.46M
Shares Change (YoY)	n/a
Shares Change (QoQ)	n/a
Owned by Insiders (%)	n/a
Owned by Institutions (%)	1.17%
Float	144,714

Valuation Ratios

The trailing PE ratio is 17.10.

PE Ratio	17.10
Forward PE	n/a
PS Ratio	0.70
PB Ratio	1.95
P/TBV Ratio	1.97
P/FCF Ratio	n/a
P/OCF Ratio	19.55
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 7.46, with an EV/FCF ratio of -65.69.

EV / Earnings	21.48
EV / Sales	0.88
EV / EBITDA	7.46
EV / EBIT	10.87
EV / FCF	-65.69

Financial Position

The company has a current ratio of 2.42, with a Debt / Equity ratio of 0.65.

Current Ratio	2.42
Quick Ratio	0.94
Debt / Equity	0.65
Debt / EBITDA	1.98
Debt / FCF	-17.47
Interest Coverage	3.82

Financial Efficiency

Return on equity (ROE) is 11.90% and return on invested capital (ROIC) is 9.01%.

Return on Equity (ROE)	11.90%
Return on Assets (ROA)	6.96%
Return on Invested Capital (ROIC)	9.01%
Return on Capital Employed (ROCE)	14.25%
Revenue Per Employee	499,709
Profits Per Employee	20,577
Employee Count	222
Asset Turnover	1.37
Inventory Turnover	1.56

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +7.20% in the last 52 weeks. The beta is 0.37, so Biogened's price volatility has been lower than the market average.

Beta (5Y)	0.37
52-Week Price Change	+7.20%
50-Day Moving Average	26.18
200-Day Moving Average	24.13
Relative Strength Index (RSI)	62.35
Average Volume (20 Days)	45

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Biogened had revenue of PLN 110.94 million and earned 4.57 million in profits. Earnings per share was 1.86.

Revenue	110.94M
Gross Profit	76.66M
Operating Income	9.03M
Pretax Income	6.82M
Net Income	4.57M
EBITDA	13.16M
EBIT	9.03M
Earnings Per Share (EPS)	1.86

Balance Sheet

The company has 6.07 million in cash and 26.10 million in debt, giving a net cash position of -20.03 million or -8.16 per share.

Cash & Cash Equivalents	6.07M
Total Debt	26.10M
Net Cash	-20.03M
Net Cash Per Share	-8.16
Equity (Book Value)	40.05M
Book Value Per Share	16.30
Working Capital	28.95M

Cash Flow

In the last 12 months, operating cash flow was 4.00 million and capital expenditures -5.49 million, giving a free cash flow of -1.49 million.

Operating Cash Flow	4.00M
Capital Expenditures	-5.49M
Free Cash Flow	-1.49M
FCF Per Share	-0.61

Margins

Gross margin is 69.10%, with operating and profit margins of 8.14% and 4.12%.

Gross Margin	69.10%
Operating Margin	8.14%
Pretax Margin	6.15%
Profit Margin	4.12%
EBITDA Margin	11.87%
EBIT Margin	8.14%
FCF Margin	n/a

Dividends & Yields

This stock pays an annual dividend of 0.50, which amounts to a dividend yield of 1.57%.

Dividend Per Share	0.50
Dividend Yield	1.57%
Dividend Growth (YoY)	25.00%
Years of Dividend Growth	3
Payout Ratio	26.89%
Buyback Yield	n/a
Shareholder Yield	1.57%
Earnings Yield	5.85%
FCF Yield	-1.91%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Biogened has an Altman Z-Score of 2.96. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	2.96
Piotroski F-Score	n/a